索拉非尼作为晚期Child-Pugh B级肝细胞癌患者一线治疗的荟萃分析
该系统综述与荟萃分析纳入30项研究共8678例接受一线索拉非尼治疗的晚期肝细胞癌患者,比较Child-Pugh A级与B级患者的疗效与安全性。结果显示Child-Pugh B级患者中位总生存期较A级更差(4.6个月 vs 8.8个月),但两组缓解率、安全性和耐受性无显著差异。
要点
- Child-Pugh B级患者中位总生存期为4.6个月,A级为8.8个月。
- 两组缓解率分别为4.2%与4.6%,无显著差异。
- Child-Pugh B级与更差的总生存期显著相关(P < 0.001)。
核心结论
- Child-Pugh B级肝功能(对比A级)与更差的总生存期相关,但一线索拉非尼的缓解率、安全性和耐受性相似,这一相似性不太可能具有临床意义。
研究设计与样本
- 系统综述与荟萃分析,纳入30项研究(4项随机对照试验、26项队列研究),共8678例接受一线索拉非尼治疗的晚期肝细胞癌患者,研究时间范围为2002年8月至2012年9月。
主要发现
- 全队列中位总生存期为7.2个月;Child-Pugh A级为8.8个月,Child-Pugh B级为4.6个月。
- 多变量荟萃回归分析显示,总生存期与ECOG体能状态2分患者比例(P = 0.04)及Child-Pugh B级肝功能(P = 0.001)呈显著负相关。
- 在4项对Child-Pugh状态进行多变量比较的研究中,Child-Pugh B级与显著更差的总生存期相关(P < 0.001)。
- Child-Pugh A级与B级患者对索拉非尼的缓解率分别为4.6%与4.2%,无差异。
- Child-Pugh A/B级患者中35%发生III/IV级不良事件(P = 0.7),无进展停药率(P = 0.31)与治疗相关死亡率(P = 0.94)在Child-Pugh B级患者中相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sorafenib has demonstrated survival benefit in first-line treatment of advanced hepatocellular carcinoma (HCC); utility of sorafenib in patients with advanced HCC and Child-Pugh B (CP-B) liver function remains a subject of debate. METHODS: A systematic review identified studies using first-line sorafenib in patients with advanced HCC and CP-A/B liver function. Meta-regression analysis comprising linear regression was conducted to explore the association between the baseline factors and overall survival (OS). Differences between efficacy/safety and tolerability parameters were explored using meta-analysis. RESULTS: Thirty studies (12 Asian) comprising 8678 patients (August 2002 - September 2012) were included (four randomised controlled trials, 26 cohort studies). Median age was 61 years and 83% were men. Hepatitis B/C status was positive in 35%/22%, respectively. The CP status was available for 8577 patients (99%); CP-A, 79% and CP-B, 19%. Median OS on sorafenib for entire cohort was 7.2 months; 8.8 months in CP-A and 4.6 months in CP-B. Multivariable meta-regression analysis showed significant negative association between OS and proportion of patients with the Eastern Cooperative Oncology Group performance status 2 (P = 0.04) and CP-B liver function (P = 0.001). Among four studies reporting multivariable comparison of the CP status, CP-B was associated with significantly worse OS (P < 0.001). There were no differences in the response rate to sorafenib between patients with CP-A (4.6%) and CP-B (4.2%) liver function. Safety and tolerability were similar; 35% of patients with CP-A/B liver function developed grade III/IV adverse events (P = 0.7). Meta-regression analysis showed similar rates of treatment discontinuation without progression (P = 0.31) and treatment-related death (P = 0.94) in patients with CP-B liver function. CONCLUSION: CP-B liver function (versus CP-A) is associated with worse OS (but the similar response rate, safety and tolerability of first-line sorafenib, is unlikely to be clinically meaningful).
引用
- McNamara MG, Slagter AE, Nuttall C, et al. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer. 2018. PMID: 30384012. doi:10.1016/j.ejca.2018.09.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。